Article
Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Leukemia & lymphoma - 1 Jul 2011
Tibes Raoul, Mesa Ruben A
Abstract excerpt
The watershed discovery of the JAK2V617F mutation in 2005, and the high prevalence of this mutation in the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), has led to a renaissance in the science and therapy of these disorders. Inhibitors of JAK2 entered clinical trials in 2007 and ushered in an unprecedented era of trials with agents specifically designed for MPNs. Currently 10 different...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.